FOCUS 1 and 2 trials: Two Phase III, randomised, double-blind, multinational, multicentre, non-inferiority trials comparing Zinforo (600 mg IV every 12 hours, adjusted for moderate renal impairment) vs ceftriaxone (1 g IV every 24 hours)²

Clinical cure rates: FOCUS 1 and 2^||

^||The lower limit of the 95% CI was above –10%, which met the predefined criteria for non-inferiority.⁷ Zinforo was well tolerated with a safety profile similar to that of ceftriaxone.⁷

^‡Zinforo may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for Zinforo.

*CrCL 31–50 mL/min.²

^† Shown not to be statistically significant.³

^§ Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.²

^**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.¹